This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Neurology  • Cerebrovascular Disease  • Cardiovascular System  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators

JAMA. 1998;279:1265-1272.

Context.— Anticoagulation with unfractionated heparin is used commonly for treatment of acute ischemic stroke, but its use remains controversial because it has not been shown to be effective or safe. Low molecular weight heparins and heparinoids have been shown to be effective in preventing deep vein thrombosis in persons with stroke, and they might be effective in reducing unfavorable outcomes following ischemic stroke.

Objective.— To test whether an intravenously administered low molecular weight heparinoid, ORG 10172 (danaparoid sodium), increases the likelihood of a favorable outcome at 3 months after acute ischemic stroke.

Design.— Randomized, double-blind, placebo-controlled, multicenter trial.

Setting and Participants.— Between December 22, 1990, and December 6, 1997, 1281 persons with acute stroke were enrolled at 36 centers across the United States.

Intervention.— A 7-day course of ORG 10172 or placebo was given initially as a bolus within 24 hours of stroke, followed by continuous infusion in addition to the best medical care. Doses were adjusted in response to anti–factor Xa activity.

Main Outcome Measures.— Favorable outcome rated as the combination of a Glasgow Outcome Scale score of I or II and a modified Barthel Index of 12 or greater on a scale of 0 to 20 at 3 months or 7 days; very favorable outcome was recorded for the combination of a Glasgow Outcome Scale of I and a Barthel Index of 19 or 20 at 3 months or 7 days.

Results.— At 3 months, 482 (75.2%) of 641 persons assigned to treatment with ORG 10172 and 467 (73.7%) of 634 patients treated with placebo had favorable outcomes (P=.49); 49.5% and 47%, respectively, of patients in each group had very favorable outcomes at 3 months. At 7 days, 376 (59.2%) of 635 persons given ORG 10172 and 344 (54.3%) of 633 receiving placebo had favorable outcomes (P=.07). For the same interval, 215 (33.9%) of 635 persons given ORG 10172 and 176 (27.8%) of 633 persons administered placebo had very favorable outcomes (P=.01; odds ratio, 1.36; 95% confidence interval, 1.06-1.73). Within 10 days of onset of treatment, serious intracranial bleeding events occurred in 14 patients given ORG 10172 (15 events) and in 4 placebo-treated patients (5 events) (P=.05).

Conclusion.— Despite an apparent positive response to treatment at 7 days, emergent administration of the antithrombotic agent, ORG 10172, is not associated with an improvement in favorable outcome at 3 months.

From the Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Stroke Treatment: Promising but Still Struggling
Louis R. Caplan
JAMA. 1998;279(16):1304-1306.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

What Is a Lacune? Dogged deja vu doggerel
Landau
Stroke 2009;40:e498-e499.
FULL TEXT  

Definition and Evaluation of Transient Ischemic Attack: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.
Easton et al.
Stroke 2009;40:2276-2293.
ABSTRACT | FULL TEXT  

Inflammatory and Hemostatic Biomarkers Associated With Early Recurrent Ischemic Lesions in Acute Ischemic Stroke
Kang et al.
Stroke 2009;40:1653-1658.
ABSTRACT | FULL TEXT  

Extending Acute Trials to Remote Populations: A Pilot Study During Interhospital Helicopter Transfer
Leira et al.
Stroke 2009;40:895-901.
ABSTRACT | FULL TEXT  

The 2008 William M. Feinberg Lecture: Prioritizing Stroke Research
Johnston
Stroke 2008;39:3431-3436.
ABSTRACT | FULL TEXT  

Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment
Stoll et al.
Blood 2008;112:3555-3562.
ABSTRACT | FULL TEXT  

Early Clinical Diagnosis of Lacunar Strokes
Toni et al.
Stroke 2008;39:e152-e152.
FULL TEXT  

71-Year-Old Woman With Loss of Right-Sided Vision and Cognitive Deficits
Barrett and Freeman
Mayo Clin Proc. 2008;83:708-711.
FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Albers et al.
Chest 2008;133:630S-669S.
ABSTRACT | FULL TEXT  

A Systematic Review of Immediate Anticoagulation for Ischemic Stroke of Presumed Cardioembolic Origin
Guedes and Ferro
Stroke 2008;39:e81-e82.
FULL TEXT  

Hyperglycemia in Patients Undergoing Cerebral Aneurysm Surgery: Its Association With Long-term Gross Neurologic and Neuropsychological Function
Pasternak et al.
Mayo Clin Proc. 2008;83:406-417.
ABSTRACT | FULL TEXT  

NINDS Clinical Trials in Stroke: Lessons Learned and Future Directions
Marler
Stroke 2007;38:3302-3307.
ABSTRACT | FULL TEXT  

Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials
Savitz et al.
Stroke 2007;38:3205-3212.
ABSTRACT | FULL TEXT  

Acute Ischemic Stroke Treatment in 2007
Goldstein
Circulation 2007;116:1504-1514.
FULL TEXT  

Antiplatelets Versus Anticoagulation in Cervical Artery Dissection
Engelter et al.
Stroke 2007;38:2605-2611.
ABSTRACT | FULL TEXT  

Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke
Kunte et al.
Stroke 2007;38:2526-2530.
ABSTRACT | FULL TEXT  

Impact of Abnormal Diffusion-Weighted Imaging Results on Short-term Outcome Following Transient Ischemic Attack
Prabhakaran et al.
Arch Neurol 2007;64:1105-1109.
ABSTRACT | FULL TEXT  

Pharmacological Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients: A Meta-analysis of Randomized Controlled Trials
Wein et al.
Arch Intern Med 2007;167:1476-1486.
ABSTRACT | FULL TEXT  

Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome
Ringleb et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:690-693.
ABSTRACT | FULL TEXT  

Intra-arterial therapies for acute ischemic stroke
Mandava and Kent
Neurology 2007;68:2132-2139.
ABSTRACT | FULL TEXT  

The time horizons of formal decision analyses
Benbassat and Baumal
QJM 2007;100:383-388.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Adams et al.
Circulation 2007;115:e478-e534.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Adams et al.
Stroke 2007;38:1655-1711.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials
Paciaroni et al.
Stroke 2007;38:423-430.
ABSTRACT | FULL TEXT  

Intracranial Hemorrhage Associated With Revascularization Therapies
Khatri et al.
Stroke 2007;38:431-440.
ABSTRACT | FULL TEXT  

Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke
McCabe and Rakhit
J. Neurol. Neurosurg. Psychiatry 2007;78:14-24.
ABSTRACT | FULL TEXT  

Silent Ischemic Lesion Recurrence on Magnetic Resonance Imaging Predicts Subsequent Clinical Vascular Events
Kang et al.
Arch Neurol 2006;63:1730-1733.
ABSTRACT | FULL TEXT  

Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation: No, but ....
Davis and Donnan
Stroke 2006;37:3056-3056.
FULL TEXT  

Predictors of recurrent stroke in African Americans.
Ruland et al.
Neurology 2006;67:567-571.
ABSTRACT | FULL TEXT  

Clot Removal Therapy by Aspiration and Extraction for Acute Embolic Carotid Occlusion
Imai et al.
Am. J. Neuroradiol. 2006;27:1521-1527.
ABSTRACT | FULL TEXT  

Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator
Cocho et al.
Stroke 2006;37:996-999.
ABSTRACT | FULL TEXT  

D-Dimer Predicts Early Clinical Progression in Ischemic Stroke: Confirmation Using Routine Clinical Assays
Barber et al.
Stroke 2006;37:1113-1115.
ABSTRACT | FULL TEXT  

Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study
Dhamoon et al.
Neurology 2006;66:641-646.
ABSTRACT | FULL TEXT  

Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials
Bruno et al.
Stroke 2006;37:920-921.
ABSTRACT | FULL TEXT  

Premorbid antiplatelet use and ischemic stroke outcomes
Sanossian et al.
Neurology 2006;66:319-323.
ABSTRACT | FULL TEXT  

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?
O'Donnell et al.
Stroke 2006;37:452-455.
ABSTRACT | FULL TEXT  

Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial
Diener et al.
Stroke 2006;37:139-144.
ABSTRACT | FULL TEXT  

Recruiting Subjects for Acute Stroke Trials: A Meta-Analysis
Elkins et al.
Stroke 2006;37:123-128.
ABSTRACT | FULL TEXT  

Hemispheric asymmetry of gaze deviation and relationship to neglect in acute stroke
Ringman et al.
Neurology 2005;65:1661-1662.
ABSTRACT | FULL TEXT  

Intravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infarctions
Camerlingo et al.
Stroke 2005;36:2415-2420.
ABSTRACT | FULL TEXT  

Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
Palesch et al.
Stroke 2005;36:2410-2414.
ABSTRACT | FULL TEXT  

Management of Adult Stroke Rehabilitation Care: A Clinical Practice Guideline
Duncan et al.
Stroke 2005;36:e100-e143.
FULL TEXT  

Current status of stroke prevention in patients with atrial fibrillation
Bath et al.
Eur Heart J Suppl 2005;7:C12-C18.
ABSTRACT | FULL TEXT  

Editorial Comment-- Time to Burn the TOAST
Landau and Nassief
Stroke 2005;36:902-904.
FULL TEXT  

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial
Abciximab Emergent Stroke Treatment Trial Investi
Stroke 2005;36:880-890.
ABSTRACT | FULL TEXT  

Heparin use in acute ischaemic stroke: does evidence change practice?
Benatar
QJM 2005;98:147-152.
FULL TEXT  

Early and late recurrence of ischemic lesion on MRI: Evidence for a prolonged stroke-prone state?
Kang et al.
Neurology 2004;63:2261-2265.
ABSTRACT | FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Albers et al.
Chest 2004;126:483S-512S.
ABSTRACT | FULL TEXT  

Poststroke Neurological Improvement Within 7 Days Is Associated With Subsequent Deterioration
Aslanyan et al.
Stroke 2004;35:2165-2170.
ABSTRACT | FULL TEXT  

Frequency, risk factors, anatomy, and course of unilateral neglect in an acute stroke cohort
Ringman et al.
Neurology 2004;63:468-474.
ABSTRACT | FULL TEXT  

Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1): A Randomized, Placebo-Controlled Safety Study
LaMonte et al.
Stroke 2004;35:1677-1682.
ABSTRACT | FULL TEXT  

Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome
Weaver et al.
Stroke 2004;35:1216-1224.
ABSTRACT | FULL TEXT  

Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease
Alberts et al.
Stroke 2004;35:175-178.
ABSTRACT | FULL TEXT  

Stroke Is Best Managed by a Neurologist: Battle of the Titans
Lees
Stroke 2003;34:2764-2765.
FULL TEXT  

Are Patients With Acutely Recovered Cerebral Ischemia More Unstable?
Johnston and Easton
Stroke 2003;34:2446-2450.
ABSTRACT | FULL TEXT  

Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients: A Randomized Trial
Gorelick et al.
JAMA 2003;289:2947-2957.
ABSTRACT | FULL TEXT  

Adding to the Effectiveness of Intravenous Tissue Plasminogen Activator for Treating Acute Stroke
Grotta
Circulation 2003;107:2769-2770.
FULL TEXT  

Homocysteine and Risk of Recurrent Stroke
Boysen et al.
Stroke 2003;34:1258-1261.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association
Adams et al.
Stroke 2003;34:1056-1083.
FULL TEXT  

Resolved: Heparin May Be Useful in Selected Patients With Brain Ischemia
Caplan
Stroke 2003;34:230-231.
FULL TEXT  

Full Heparin Anticoagulation Should Not Be Used in Acute Ischemic Stroke
Sandercock
Stroke 2003;34:231-232.
FULL TEXT  

Transient Ischemic Attack
Johnston
NEJM 2002;347:1687-1692.
FULL TEXT  

Atrial Fibrillation, Stroke, and Acute Antithrombotic Therapy: Analysis of Randomized Clinical Trials
Hart et al.
Stroke 2002;33:2722-2727.
ABSTRACT | FULL TEXT  

Treatment of Acute Ischemic Stroke: Part II: Neuroprotection and Medical Management
Broderick and Hacke
Circulation 2002;106:1736-1740.
FULL TEXT  

Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association)
Coull et al.
Neurology 2002;59:13-22.
FULL TEXT  

Considering the Role of Heparin and Low-Molecular-Weight Heparins in Acute Ischemic Stroke
Moonis and Fisher
Stroke 2002;33:1927-1933.
ABSTRACT | FULL TEXT  

Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association)
Coull et al.
Stroke 2002;33:1934-1942.
FULL TEXT  

Use of Intravenous Heparin by North American Neurologists: Do the Data Matter?
Al-Sadat et al.
Stroke 2002;33:1574-1577.
ABSTRACT | FULL TEXT  

Treatment of Patients With Stroke
Caplan
Arch Neurol 2002;59:703-707.
FULL TEXT  

Alcohol, Ischemic Stroke, and Lessons From a Negative Study
Dulli
Stroke 2002;33:890-891.
FULL TEXT  

Validation of a Weight-Based Nomogram for the Use of Intravenous Heparin in Transient Ischemic Attack or Stroke
Toth and Voll
Stroke 2002;33:670-674.
ABSTRACT | FULL TEXT  

Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke
Adams
Stroke 2002;33:856-861.
ABSTRACT | FULL TEXT  

Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke
Toomey et al.
Stroke 2002;33:578-585.
ABSTRACT | FULL TEXT  

Fluid-Attenuated Inversion Recovery and Diffusion- and Perfusion-Weighted MRI Abnormalities in 117 Consecutive Patients With Stroke Symptoms Editorial Comment
Perkins et al.
Stroke 2001;32:2774-2781.
ABSTRACT | FULL TEXT  

Effect of Prior Aspirin Use on Stroke Severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
Wilterdink et al.
Stroke 2001;32:2836-2840.
ABSTRACT | FULL TEXT  

Risk Factors, Outcome, and Treatment in Subtypes of Ischemic Stroke: The German Stroke Data Bank
Grau et al.
Stroke 2001;32:2559-2566.
ABSTRACT | FULL TEXT  

Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial
Saxena et al.
Stroke 2001;32:2333-2337.
ABSTRACT | FULL TEXT  

Predictors of Fatal Brain Edema in Massive Hemispheric Ischemic Stroke
Kasner et al.
Stroke 2001;32:2117-2123.
ABSTRACT | FULL TEXT  

Trends in Acute Ischemic Stroke Trials Through the 20th Century
Kidwell et al.
Stroke 2001;32:1349-1359.
ABSTRACT | FULL TEXT  

Improving the Reliability of Stroke Subgroup Classification Using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Criteria Editorial Comment : Classifying the Mechanisms of Ischemic Stroke
Goldstein et al.
Stroke 2001;32:1091-1097.
ABSTRACT | FULL TEXT  

Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials
Uchino et al.
Stroke 2001;32:909-916.
ABSTRACT | FULL TEXT  

Enoxaparin in Experimental Stroke : Neuroprotection and Therapeutic Window of Opportunity
Mary et al.
Stroke 2001;32:993-999.
ABSTRACT | FULL TEXT  

Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study
Longstreth et al.
Neurology 2001;56:368-375.
ABSTRACT | FULL TEXT  

Treatment of Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin : Results of the TOPAS Trial
Diener et al.
Stroke 2001;32:22-29.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment
Levine et al.
Chest 2001;119:108S-121S.
FULL TEXT  

Prevention of Venous Thromboembolism
Geerts et al.
Chest 2001;119:132S-175S.
FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Albers et al.
Chest 2001;119:300S-320S.
FULL TEXT  

Stroke: Management and Rehabilitation: Part III of III
Tegos et al.
ANGIOLOGY 2000;51:977-984.
ABSTRACT  

Low molecular weight heparins for arterial thrombosis
Nenci and Minciotti
Vasc Med 2000;5:251-258.
ABSTRACT  

Lubeluzole in Acute Ischemic Stroke Treatment : A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo
Diener et al.
Stroke 2000;31:2543-2551.
ABSTRACT | FULL TEXT  

Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia
Kalafut et al.
Stroke 2000;31:2563-2568.
ABSTRACT | FULL TEXT  

Treatment of Acute Ischemic Stroke
Brott and Bogousslavsky
NEJM 2000;343:710-722.
FULL TEXT  

Diffusion-Weighted Magnetic Resonance Imaging Identifies the "Clinically Relevant" Small-Penetrator Infarcts
Oliveira-Filho et al.
Arch Neurol 2000;57:1009-1014.
ABSTRACT | FULL TEXT  

Low-Molecular-Weight Heparins and Heparinoids in Acute Ischemic Stroke : A Meta-Analysis of Randomized Controlled Trials
Bath et al.
Stroke 2000;31:1770-1778.
ABSTRACT | FULL TEXT  

Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke
MUIR et al.
QJM 2000;93:359-364.
ABSTRACT | FULL TEXT  

Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice
Duncan et al.
Stroke 2000;31:1429-1438.
ABSTRACT | FULL TEXT  

Intravenous heparin for acute stroke: What can we learn from the megatrials?
Estol and Swanson
Neurology 2000;54:1542-1546.
FULL TEXT  

Abciximab in Acute Ischemic Stroke : A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Investigators
Stroke 2000;31:601-609.
ABSTRACT | FULL TEXT